ertugliflozin

Description: Ertugliflozin (formerly known as also known as PF-04971729; trade name: Steglatro) is an orally active and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2). In 2017, Ertugliflozin was approved by FDA to improve glycemic control in adults with type 2 diabetes mellitus. First-in-human studies after oral administration indicated that the human pharmacokinetics/dose predictions for PF-04971729 were in the range that is likely to yield a favorable pharmacodynamic response. Ertugliflozin (1-25?mg/day) improved glycaemic control, body weight and blood pressure in patients with T2DM suboptimally controlled on metformin, and was well tolerated.

References: J Med Chem. 2011 Apr 28; 54(8):2952-60; Drug Metab Dispos. 2013 Feb; 41(2):445-56; Drug Metab Dispos. 2011 Sep; 39(9):1609-19.

Related CAS#:1210344-83-4 (Ertugliflozin pidolate)